Financial Contrast: MiNK Therapeutics (NASDAQ:INKT) and Replimune Group (NASDAQ:REPL)

MiNK Therapeutics (NASDAQ:INKT) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Profitability

This table compares MiNK Therapeutics and Replimune Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-189.14%
Replimune Group	N/A	-53.12%	-41.49%

Institutional & Insider Ownership

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 19.7% of MiNK Therapeutics shares are held by company insiders. Comparatively, 8.8% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

MiNK Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Valuation and Earnings

This table compares MiNK Therapeutics and Replimune Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46 million	($0.39)	-1.85
Replimune Group	N/A	N/A	-$215.79 million	($3.05)	-4.61

Replimune Group is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MiNK Therapeutics and Replimune Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0	0	2	0	3.00
Replimune Group	0	0	6	1	3.14

MiNK Therapeutics currently has a consensus target price of $6.50, suggesting a potential upside of 802.65%. Replimune Group has a consensus target price of $17.00, suggesting a potential upside of 21.00%. Given MiNK Therapeutics’ higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Replimune Group.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About Replimune Group

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.